Antitumor Activity of Nanoparticles Loaded with PHT-427, a Novel AKT/PDK1 Inhibitor, for the Treatment of Head and Neck Squamous Cell Carcinoma

Currently, new treatments are required to supplement the current standard of care for head and neck squamous cell carcinoma (HNSCC). The phosphatidylinositol3-kinase (PI3K) signaling pathway is commonly altered and activated in HNSCC. PHT-427 is a dual PI3K-mammalian target of the AKT/PDK1 inhibitor...

Full description

Bibliographic Details
Main Authors: Joaquín Yanes-Díaz, Raquel Palao-Suay, María Rosa Aguilar, Juan Ignacio Riestra-Ayora, Antonio Ferruelo-Alonso, Luis Rojo del Olmo, Blanca Vázquez-Lasa, Ricardo Sanz-Fernández, Carolina Sánchez-Rodríguez
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Pharmaceutics
Subjects:
AKT
Online Access:https://www.mdpi.com/1999-4923/13/8/1242